Lifecore Biomedical Inc（LFCR）の財務LFCRLifecore Biomedical Inc

Lifecore Biomedical, Inc. (LFCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HA manufacturing, accounting for 54.5% of total sales, equivalent to $18.61M. Another important revenue stream is CDMO. Understanding this composition is critical for investors evaluating how LFCR navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Lifecore Biomedical, Inc. maintains a gross margin of 35.34%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.16%, while the net margin is -18.02%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LFCR converts its operational activities into shareholder value.

In the context of the broader market, LFCR competes directly with industry leaders such as MENS and MDWD. With a market capitalization of $178.67M, it holds a significant position in the sector. When comparing efficiency, LFCR's gross margin of 35.34% stands against MENS's N/A and MDWD's 10.90%. Such benchmarking helps identify whether Lifecore Biomedical, Inc. is trading at a premium or discount relative to its financial performance.

Lifecore's Q2 2026 revenue was $34.2 million, down from $36.4 million in Q4 2025, reflecting ongoing challenges. The gross margin improved to 35.34% in Q2 2026, but the company still reported a net loss of $7.1 million, highlighting profitability issues.